SGLT2 vs GLP-1 for Diabetic CKD: Post-Metformin Drug Selection
Asked Jun 26, 2026Modified 2 days agoViewed 6 timesWorks with: GPT-4, Claude 3.5 Sonnet, Gemini 1.5 Pro
0
What this prompt does
Compares SGLT2 inhibitors and GLP-1 agonists head-to-head for a patient with CKD, ischemic heart disease, and metformin intolerance, anchored to 2023 ADA and KDIGO guidelines.
- Compatible models:
- GPT-4, Claude 3.5 Sonnet, Gemini 1.5 Pro
- Category:
- Other
Compares SGLT2 inhibitors and GLP-1 agonists head-to-head for a patient with CKD, ischemic heart disease, and metformin intolerance, anchored to 2023 ADA and KDIGO guidelines. Use this when you need evidence-based second-line diabetes therapy recommendations for patients with complex comorbidities.
For a 50-year-old male with type 2 diabetes, ischemic heart disease, and stage 3 chronic kidney disease (CKD) (estimated glomerular filtration rate: eGFR 50 ml/min/1.73m²), who cannot tolerate metformin, what are the recommended pharmacological alternatives per 2023 ADA and KDIGO guidelines? Compare the renal and cardiovascular benefits of sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for this profile.
Prompt Curator
120rep · asked Jun 26, 2026
0 Responses
Want to respond? Log in.